Tag Archives: Tandospirone

Overview of New Anxiolytics

Although the benzodiazepines have been the treatment of choice for anxiety disorders for many years, unfavorable aspects to their side-effect profile have initiated efforts to develop new-generation antianxiety agents. Over the past decade, scientists have been searching for compounds that retain the robust anxiolytic efficacy of benzodiazepines, but lack a number of unwanted properties, including… Read More »

Serotonergic Drugs

Moclobemide • The compound patent was filed in 1976 by Hoffmann-La Roche • Launched in 1990 for the treatment of depression and in 1994 for treat social anxiety by Roche • Unlike other reversible inhibitors of monoamine oxidase, possible side-effects of moclobemide do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia Buspirone… Read More »

Antipsychotics For The Treatment Of Schizophrenia

Following the Anatomical Therapeutic Chemical (ATC) classification system by WHO Collaborating Centre for Drug Statistics Methodology), antipsychotics (ATC N05A) are classified as: • N05AA Phenothiazines with aliphatic side-chain: Chlorpromazine, Levomepromazine, Promazine, Triflupromazine, Cyamemazine, Chlorproethazine • N05AB Phenothiazines with piperazine structure: Dixyrazine, Fluphenazine, Perphenazine, Prochlorperazine, Thiopropazate, Trifluoperazine, Acetophenazine, Thioproperazine, Butaperazine, Perazine • N05AC Phenothiazines with piperidine… Read More »

Typical Antipsychotics For The Treatment Of Schizophrenia

Lithium • Lithium and lithium salts (especially carbonate or citrate) were the focus of research in depression topic in the 1930’s. Lithium carbonate was launched in 1939 by Solvay for the treatment of depression and schizophrenia, and in 2002 Glaxo launched it for the treatment of mania • For many years, the effect of lithium… Read More »